Gait Change Often Arrives First in Idiopathic Normal Pressure Hydrocephalus
Idiopathic normal pressure hydrocephalus is one of the few neurologic syndromes in older adults where a progressive walking disorder can open a path to treatment. The disorder is defined by cerebral ventricular enlargement and the familiar triad of gait impairment, urinary dysfunction, and cognitive decline, but the clinical picture rarely presents in a textbook sequence. Gait disturbance usually comes first, and it does so with a pattern that clinicians recognize quickly once they have seen it: broad-based steps, slowed pace, shuffling, and trouble turning. In practice, that matters because the earliest motor change may be the most actionable clue.
Prevalence rises sharply with age. Among adults 65 years and older, iNPH affects about 1% to 4%, and among those 80 years and older the estimate climbs to 6% to 8%. Those numbers place the syndrome squarely in the category of common and underrecognized causes of disability in later life, especially because symptoms overlap with Parkinsonism, vascular cognitive impairment, frailty, and the effects of comorbid disease. The disorder is progressive, but not every patient progresses in the same way or at the same speed.
The Symptom Triad Rarely Advances at the Same Pace
Gait impairment appears in 85% to 95% of patients and is often the earliest symptom. Urinary dysfunction follows in roughly 75% to 90%, usually as urgency, nocturia, urge incontinence, or leakage. Cognitive impairment is reported in 60% to 80% of patients and tends to affect attention, processing speed, working memory, verbal fluency, and cognitive flexibility more than dense amnesia. These cognitive features point toward a frontal-subcortical pattern rather than a primary cortical amnestic syndrome, which helps explain why families may first describe slowed thinking, reduced initiative, or difficulty multitasking rather than clear-cut memory loss.
The underlying biology is multifactorial. CSF circulation abnormalities interact with vascular dysfunction and white matter injury, creating a disorder that behaves like more than a simple pressure problem. Ventricular enlargement is central to the diagnosis, but it does not by itself explain who worsens, who improves, or who responds best to diversion. White matter injury and impaired cerebrovascular reserve likely contribute to the gait disorder and executive dysfunction, while chronic periventricular stress may compound urinary symptoms through disrupted frontal pathways.
Imaging Supports the Diagnosis, But It Does Not Predict Recovery Reliably
Brain magnetic resonance imaging remains the most useful imaging tool, showing ventricular and subarachnoid space enlargement characteristic of the syndrome. Yet those findings do not reliably map onto treatment response. A patient can have impressive ventricular enlargement and still respond poorly, while another with comparable imaging can improve noticeably after cerebrospinal fluid removal. In that sense, imaging establishes the syndrome, but bedside physiology still determines whether shunting is likely to help.
Early diagnosis matters because shorter symptom duration and less advanced disease are associated with better outcomes. Delayed recognition allows gait instability, falls, and deconditioning to accumulate, and once disability becomes entrenched, the chance of meaningful recovery falls. The practical consequence is straightforward: older adults with a broad-based shuffling gait, impaired turning, and new urinary symptoms should not be routed through a prolonged diagnostic detour before iNPH is considered.
Large-Volume Lumbar Puncture Remains the First Prognostic Test
Patients being evaluated for iNPH should undergo large-volume lumbar puncture with removal of 30 to 50 mL of cerebrospinal fluid. The purpose is twofold: confirm the diagnosis and predict shunt responsiveness. Improvement is measured with objective gait testing and can begin within hours after drainage. The speed of that response is clinically important. A rapid gait change after CSF removal is one of the strongest bedside signals that the downstream motor circuit remains modifiable rather than irreversibly damaged.
When the clinical picture remains convincing but the lumbar puncture response is negative or equivocal, extended lumbar drainage provides a stronger prognostic readout. This approach removes 200 to 300 mL of CSF over several days in the inpatient setting and offers higher accuracy for predicting shunt benefit. The tradeoff is the greater procedural burden, but the test can prevent both false reassurance and unnecessary surgery in patients whose symptoms are less likely to respond.
A negative tap test does not always close the door.
Shunt Surgery Still Delivers the Main Therapeutic Gain
Treatment for iNPH is CSF diversion with shunt placement. Ventriculoperitoneal shunts are the most common approach, although ventriculoatrial and lumboperitoneal shunts may have similar efficacy. After shunting, about 75% to 80% of patients have improvement in gait velocity, while cognitive and urinary gains occur in approximately 50% to 70%. The asymmetry is important: gait is usually the most responsive domain, and clinicians should not expect cognition or bladder function to improve to the same degree or with the same consistency.
The mechanism is plausible. By diverting cerebrospinal fluid and reducing chronic mechanical distortion, shunting may restore more favorable periventricular dynamics and improve the function of motor and frontal-subcortical pathways. In patients whose disability is being driven by reversible CSF-related stress rather than fixed neurodegeneration, gait can improve quickly and visibly. When the gait response is strong, it often validates the entire diagnostic pathway retrospectively.
Shunt Complications Require Realistic Counseling and Follow-Up
The procedure is not benign. Overdrainage and underdrainage occur in 10% to 30% of patients and can present with postural headaches or subdural collections. Recurrence or worsening of iNPH symptoms, shunt malfunction, and shunt infections also remain important concerns, with malfunction reported in 10% to 20% of patients. These risks reinforce the need for careful patient selection, symptom tracking, and follow-up after surgery.
Shunt management is therefore not a one-time intervention but an ongoing clinical commitment. A patient who improves after surgery may later deteriorate because of mechanical failure, drainage imbalance, or progression of another neurologic process that was present from the start. That is one reason postoperative gait monitoring matters so much: a renewed decline may reflect a treatable shunt problem rather than irreversible neurologic loss.
Why This Disorder Still Gets Missed
iNPH sits at the intersection of neurology, geriatrics, and functional decline. Its symptoms resemble common age-related problems, but unlike many neurodegenerative disorders, it has a potentially reversible component. The challenge is recognizing when the triad is present, when the gait syndrome is compatible, and when the patient is still early enough in the course to benefit from testing and shunting. Objective gait assessment after CSF removal remains the most practical way to separate those who are likely to improve from those whose symptoms are already too advanced or too mixed with other causes to respond well.
For clinicians, the central message is not subtle: older adults with new gait slowing, urinary urgency, and executive dysfunction deserve a focused evaluation for iNPH before the syndrome becomes irreversible. The review also leaves a familiar limitation in place: imaging can support the diagnosis, but clinical selection and physiologic testing still determine who improves after diversion and who does not.